Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
R De Caterina, P Kelly, P Monteiro… - Journal of …, 2019 - journals.lww.com
Aim Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
approved for the prevention of stroke and systemic embolism in adult patients with atrial …
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in …
R De Caterina, P Kelly, P Monteiro, JC Deharo… - BMC cardiovascular …, 2019 - Springer
Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have
substantially improved anticoagulation therapy for prevention of stroke and systemic …
substantially improved anticoagulation therapy for prevention of stroke and systemic …
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY
C Köhler, L Tittl, S Marten, C Naue, M Spindler… - Thrombosis …, 2022 - Elsevier
Background Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for
stroke prevention in atrial fibrillation (SPAF). Outcome data on clinical effectiveness and …
stroke prevention in atrial fibrillation (SPAF). Outcome data on clinical effectiveness and …
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
JR de Groot, TW Weiss, P Kelly… - European Heart …, 2021 - academic.oup.com
Aims Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in
patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine …
patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine …
Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort
Aims Edoxaban treatment for stroke prevention in atrial fibrillation (AF) has mainly been
investigated in randomized controlled trials, and data reflecting clinical practice are limited …
investigated in randomized controlled trials, and data reflecting clinical practice are limited …
Safety and effectiveness of edoxaban in atrial fibrillation patients in routine clinical practice: one-year follow-up from the global noninterventional ETNA-AF program
R De Caterina, YH Kim, Y Koretsune, CC Wang… - Journal of Clinical …, 2021 - mdpi.com
Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for
stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in …
stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in …
Edoxaban in patients with atrial fibrillation
A Eisen, CT Ruff - Therapeutic advances in cardiovascular …, 2017 - journals.sagepub.com
Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and
treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF) …
treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF) …
Edoxaban for the prevention of stroke in patients with atrial fibrillation
CE Cervantes, JL Merino, V Barrios - Expert Review of …, 2019 - Taylor & Francis
Introduction: Edoxaban is the last direct oral anticoagulant marketed for the prevention of
stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF …
stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF …
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
Aims Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from
cardiovascular complications including cardiovascular death, stroke, and major bleeding. To …
cardiovascular complications including cardiovascular death, stroke, and major bleeding. To …
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation
N Chung, HK Jeon, LM Lien, WT Lai… - Thrombosis and …, 2011 - thieme-connect.com
Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for
the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate …
the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate …
相关搜索
- edoxaban treatment atrial fibrillation
- clinical outcomes atrial fibrillation
- stroke prevention atrial fibrillation
- effectiveness and safety atrial fibrillation
- edoxaban treatment design and rationale
- design and rationale atrial fibrillation
- edoxaban treatment characteristics of patients
- characteristics of patients atrial fibrillation
- effectiveness of edoxaban fibrillation patients
- safety of edoxaban asian patients
- edoxaban in patients atrial fibrillation
- edoxaban for the prevention atrial fibrillation
- stroke in patients atrial fibrillation
- edoxaban therapy atrial fibrillation
- safety of edoxaban atrial fibrillation
- effectiveness and safety edoxaban in patients